Hepatic Resection for the Carcinoid Syndrome in Patients with Severe Carcinoid Heart Disease: Does Valve Replacement Permit Safe Hepatic Resection? - 10/08/11

Doi : 10.1016/j.jamcollsurg.2011.03.029

Joseph B. Lillegard, MD, PhD ^a, James E. Fisher, MD ^a, Travis J. Mckenzie, MD ^a, Florencia G. Que, MD, FACS ^a, Michael B. Farnell, MD, FACS ^a, Michael L. Kendrick, MD, FACS ^a, John H. Donohue, MD, FACS ^a, Kaye Reid-Lombardo, MD, FACS ^a, Hartzell V. Schaff, MD, FACS ^b, Heidi M. Connolly, MD ^c, David M. Nagorney, MD, FACS ^a,^⁎
^a Division of Gastroenterologic and General Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN
^b Division of Cardiovascular Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN
^c Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN

Correspondence address: David M Nagorney, MD, FACS, Department of Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905

Résumé

Background

Hepatic resection of metastatic carcinoid cancer can prolong survival and control symptomatic endocrinopathy. Decompensated carcinoid heart disease (CHD) can develop in some patients with metastatic carcinoid cancers, which can preclude operation for resectable hepatic metastases. We hypothesized that outcomes after hepatic resection for patients with the carcinoid syndrome after valve replacement for CHD would be similar to carcinoid patients without CHD.

Study Design

We compared the survival and symptom control after hepatic resection for patients undergoing valve replacement for CHD to carcinoid patients without CHD matched for age, sex, and extent of hepatectomy.

Results

Fourteen patients with earlier valve replacement for CHD were compared with 28 carcinoid patients without CHD. All patients had hepatic resection for metastatic carcinoid disease and carcinoid syndrome. Mean age, sex distribution, and extent of hepatectomy (major hepatectomy, 78%) was similar between groups. Mean interval from valve replacement to hepatectomy was 101 days. There was no operative mortality. Major operative morbidity, inclusive of operative blood loss and cardiorespiratory events, occurred in 28.5% and 14.2% for CHD and non-CHD groups, respectively (p = 0.16). Symptom-free survival for CHD and non-CHD groups was 69% and 81% at 1 year (p = 0.22) and 61% and 44% (p = 0.17) at 5 years, respectively. Octreotide-free survival after hepatectomy 69% and 84% (p = 0.15) at 1 year and 62% and 52% (p = 0.29) 5 years, respectively. Overall survival CHD and non-CHD groups 100% at 1 year and 100% and 70% (p = 0.002) 5 years.

Conclusions

Valve replacement for severe CHD is safe and hepatic resection is associated with similar outcomes as patients without CHD undergoing hepatic resection for carcinoid syndrome. Identifying resectable hepatic metastases from carcinoids in patients with severe CHD should prompt valve replacement and interval hepatic resection.

Le texte complet de cet article est disponible en PDF.